1. Clinical profile of ceftobiprole, a novel β-lactam antibiotic
G.J. Noel 
Clinical Microbiology and Infection 
Volume 13, Pages (June 2007)
DOI: /j x
Copyright © 2007 European Society of Clinical Infectious Diseases Terms and Conditions

2. FIG. 1
Crystal structure of ceftobiprole bound to the active site of Staphylococcus aureus penicillin-binding protein 2′. Courtesy of M. Page, Basilea Pharmaceutica Ltd, Basel, Switzerland.
Clinical Microbiology and Infection  , 25-29DOI: ( /j x)
Copyright © 2007 European Society of Clinical Infectious Diseases Terms and Conditions

3. FIG. 2
Ceftobiprole activity against (a) Gram-positive (46th ICAAC, abstract E-116) and (b) Gram-negative (Enterobacteriaceae) isolates (15th ECCMID, abstract P-1569). CoNS MR, methicillin-resistant/coagulase-negative staphylococci; CoNS MS, methicillin-susceptible/coagulase-negative staphylococci; MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible S. aureus.
Clinical Microbiology and Infection  , 25-29DOI: ( /j x)
Copyright © 2007 European Society of Clinical Infectious Diseases Terms and Conditions

4. FIG. 3
AUC and Cmax of single ascending doses of ceftobiprole prodrug [3].
Clinical Microbiology and Infection  , 25-29DOI: ( /j x)
Copyright © 2007 European Society of Clinical Infectious Diseases Terms and Conditions